Herpes zoster and postherpetic neuralgia in older adults
- PMID: 17631237
- PMCID: PMC4859150
- DOI: 10.1016/j.cger.2007.03.003
Herpes zoster and postherpetic neuralgia in older adults
Abstract
Herpes zoster (HZ) afflicts millions of older adults annually and causes significant suffering from acute and chronic pain, or postherpetic neuralgia (PHN). HZ is caused by the reactivation of varicella-zoster virus (VZV) in sensory ganglia in the setting of age, disease, and drug-related decline in cellular immunity. VZV-induced neuronal destruction and inflammation cause the pain, interference with activities of daily living, and reduced quality of life. The optimal treatment of HZ requires early antiviral therapy and pain management. For PHN, evidence-based pharmacotherapy can reduce pain burden. The zoster vaccine is effective in reducing pain burden and preventing HZ and PHN in older adults.
Similar articles
-
Herpes Zoster.Clin Geriatr Med. 2016 Aug;32(3):539-53. doi: 10.1016/j.cger.2016.02.011. Epub 2016 Apr 9. Clin Geriatr Med. 2016. PMID: 27394022 Review.
-
Herpes zoster and postherpetic neuralgia.Expert Rev Vaccines. 2010 Mar;9(3 Suppl):21-6. doi: 10.1586/erv.10.30. Expert Rev Vaccines. 2010. PMID: 20192714 Review.
-
Herpes zoster in older adults.Clin Infect Dis. 2001 May 15;32(10):1481-6. doi: 10.1086/320169. Epub 2001 Apr 17. Clin Infect Dis. 2001. PMID: 11317250 Review.
-
Herpes zoster (shingles) and postherpetic neuralgia.Mayo Clin Proc. 2009 Mar;84(3):274-80. doi: 10.4065/84.3.274. Mayo Clin Proc. 2009. PMID: 19252116 Free PMC article. Review.
-
Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management.Drugs Aging. 2007;24(1):1-19. doi: 10.2165/00002512-200724010-00001. Drugs Aging. 2007. PMID: 17233544 Review.
Cited by
-
Zoster vaccine live for the prevention of shingles in the elderly patient.Clin Interv Aging. 2008;3(2):241-50. doi: 10.2147/cia.s1225. Clin Interv Aging. 2008. PMID: 18686747 Free PMC article. Review.
-
The role of social determinants in timely herpes zoster vaccination among older American adults.Hum Vaccin Immunother. 2021 Jul 3;17(7):2043-2049. doi: 10.1080/21645515.2020.1856598. Epub 2021 Jan 30. Hum Vaccin Immunother. 2021. PMID: 33517829 Free PMC article.
-
Chronic medical conditions as risk factors for herpes zoster.Mayo Clin Proc. 2012 Oct;87(10):961-7. doi: 10.1016/j.mayocp.2012.05.021. Mayo Clin Proc. 2012. PMID: 23036671 Free PMC article.
-
Persistence of a T Cell Infiltrate in Human Ganglia Years After Herpes Zoster and During Post-herpetic Neuralgia.Front Microbiol. 2019 Sep 11;10:2117. doi: 10.3389/fmicb.2019.02117. eCollection 2019. Front Microbiol. 2019. PMID: 31572325 Free PMC article.
-
Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.Clin Drug Investig. 2010;30(2):71-87. doi: 10.2165/11533310-000000000-00000. Clin Drug Investig. 2010. PMID: 20067326 Clinical Trial.
References
-
- Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–1349. - PubMed
-
- Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84. - PubMed
-
- Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:RR–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical